Efficacy of Simultaneous Usage of Bevacizumab and Silicone Oil Injection After Vitrectomy in Diabetic Tractional Retinal Detachment

Document Type : Original Article

Authors

¹ Assistant Professor of Ophthalmology, Department of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran

² Associate Professor of Ophthalmology, Department of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran

³ 3Research Associate, Department of Ophthalmology, Bina Eye Hospital Research Center, Tehran, Iran

⁴ Department of Ophthalmology, Bina Eye Hospital Research Center, Tehran, Iran

10.30483/rijm.2016.118363

Abstract

Background: Tractional retinal detachment (TRD), a major vision threatening complication, is one of the most common eye emergencies. The most common cause of TRD is proliferative diabetic retinopathy (PDR). The aim of this study was to evaluate the effect of simultaneous usage of bevacizumab and silicone oil injection after vitrectomy for the treatment of diabetic tractional retinal detachment.

Methods: Twenty five patients (25 eyes) with severe proliferative diabetic retinopathy were recruited into the study. All eyes underwent a single intravitreal injection of bevacizumab 1.25 mg in 0.05 mL along with silicone oil injection after vitrectomy for the management of tractional retinal detachment or vitreous hemorrhage due to severe proliferative diabetic retinopathy. Patients were then scheduled for postoperative clinical examinations at one, three and six months. The main outcome measures were regression of neovascularization, intraocular pressure, visual acuity and retinal reattachment.

Results: This study evaluated 25 eyes of 25 patients (12 men, 13 women) with a mean age of 55.686.94 years (range 21 to 49 years). In all eyes visual acuity improved and retinal attachment was accomplished. The mean preoperative visual acuity was 2.01 0.03 Log MAR which significantly improved to 1.10 0.50 Log MAR in 6th month after surgery (P < 0.000). Active neovascularization regressed significantly (P < 0.004) and intraocular pressure was controlled in 88% of patients.

Conclusions: The findings of our study may suggest that simultaneous injection of Bevacizumab and silicone oil after vitrectomy improve early results. We have found it to be particularly useful in diabetic eyes with tractional detachments of short duration.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1.Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611. [PubMed: 15294883]. https://doi.org/10.1210/er.2003-0027 PMid:15294883

2. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. 1987;105(4):497-502. [PubMed: 2436603]. https://doi.org/10.1001/archopht.1987.01060040067035 PMid:2436603

3. Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989;96(10):1495-500. [PubMed: 2587044]. https://doi.org/10.1016/S0161-6420(89)32700-X PMid:2587044

4. Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. Ophthalmology. 1983;90(5):522- 30. https://doi.org/10.1016/S0161-6420(83)34540-1 PMid:6192378

5. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91(12):1485-9. [PubMed: 6521989]. https://doi.org/10.1016/S0161-6420(84)34099-4 PMid:6521989

6. Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology. 1986;93(1):39-44. [PubMed: 2419815]. https://doi.org/10.1016/S0161-6420(86)33791-6 PMid:2419815

7. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26(6):699-700. [PubMed: 16829817]. https://doi.org/10.1097/01.iae.0000225351.87205.69 PMid:16829817

8. Khafagy A. Role of adjunctive use of intravitreal bevacizumab for severe proliferative diabetic retinopathy before vitrectomy. Med J Cairo Univ. 2011;79(2).

9. Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (Lond). 2014;28(5):576-80. [PubMed: 24556886]. https://doi.org/10.1038/eye.2014.21 PMid:24556886 PMCid:PMC4017106

10. Yeh PT, Yang CH, Yang CM. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy.Acta Ophthalmol. 2011;89(7):634-40. [PubMed: 20064118]. https://doi.org/10.1111/j.1755-3768.2009.01821.x PMid:20064118

11. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond). 2009;23(1):108-11. [PubMed: 17891057]. https://doi.org/10.1038/sj.eye.6702983 PMid:17891057

12. Abu El-Asrar AM, Al-Bishi SM, Kangave D. Outcome of temporary silicone oil tamponade in complex rhegmatogenous retinal detachment. Eur J Ophthalmol. 2003;13(5):474-81. [PubMed: 12841571]. https://doi.org/10.1177/112067210301300509 PMid:12841571

13. Ghazi NG, Green WR. Pathology and pathogenesis of retinal detachment. Eye (Lond). 2002;16(4):411-21. [PubMed: 12101448]. https://doi.org/10.1038/sj.eye.6700197 PMid:12101448

14. Xu Y, You Y, Du W, Zhao C, Li J, Mao J, et al. Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci. 2012;53(9):5221-6. [PubMed: 22786911]. https://doi.org/10.1167/iovs.12-9702 PMid:22786911 PMCid:PMC3416031

15. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767-76. [PubMed: 11581047] quiz1777, 1800. https://doi.org/10.1016/S0161-6420(01)00775-8 PMid:11581047

16. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571-80. [PubMed: 18440643] 1580 e1-3. https://doi.org/10.1016/j.ophtha.2008.02.026 PMid:18440643

17. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(1):155-8. [PubMed: 16815267]. https://doi.org/10.1016/j.ajo.2006.02.015 PMid:16815267

18. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116(10):1943-8. [PubMed: 19699531]. https://doi.org/10.1016/j.ophtha.2009.07.001 PMid:19699531

19. Lo WR, Kim SJ, Aaberg TM Sr, Bergstrom C, Srivastava SK, Yan J, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. 2009;29(7):926-31. [PubMed: 19584650]. https://doi.org/10.1097/IAE.0b013e3181a8eb88 PMid:19584650 PMCid:PMC3033782

20. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29(6):768-74. [PubMed: 19516117]. https://doi.org/10.1097/IAE.0b013e3181a3b7ef PMid:19516117

21. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125(10):1363-6. [PubMed: 17923544]. 4 Razavi Int J Med. 2017; 5(2):e43217. Alishiri A et al. https://doi.org/10.1001/archopht.125.10.1363 PMid:17923544

22. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213-6. [PubMed: 17965108]. https://doi.org/10.1136/bjo.2007.127142 PMid:17965108

23. Jampol LM, Shankle J, Schroeder R, Tornambe P, Spaide RF, Hee MR. Diagnostic and therapeutic challenges. Retina. 2006;26(9):1072-6. [PubMed: 17151497]. https://doi.org/10.1097/01.iae.0000248819.86737.a5 PMid:17151497

24. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26(9):1006-13. [PubMed: 17151487]. https://doi.org/10.1097/01.iae.0000246884.76018.63 PMid:17151487

25. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695 e1- 15. [PubMed: 17011951]. https://doi.org/10.1016/j.ophtha.2006.05.064 PMid:17011951

Razavi International Journal of Medicine

Volume 5, Issue 2
June 2017

Files

Share

How to cite

Statistics

Article View: 1,331
PDF Download: 110